TipRanks on MSN
Larimar Therapeutics Reports Promising Clinical Data Update
Larimar Therapeutics ( ($LRMR) ) has shared an update. On October 14, 2025, Larimar Therapeutics announced updated clinical data for nomlabofusp, ...
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injec ...
As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...
The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws.
Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a ...
Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich's ataxia and uncertainty about its functional benefits. The stock has dropped over 50% ...
“We are pleased to share these two recent publications featuring nonclinical findings that provide evidence of nomlabofusp’s mechanism of action, its ability to increase FXN levels in disease-relevant ...
Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with Friedreich’s ataxia (FA) Modeling and simulation ...
In Echoes of the Earth, Rhea Poddar Loyalka redefines gemstone jewellery as a poetic homage to nature’s raw beauty. Think hand-carved tourmalines, spring-set leaves, and rare gems like Australian ...
Shares of Larimar Therapeutics rose in premarket trading after the company said it would share data from its study for its proposed treatment of Friedreich's ataxia, a neurodegenerative disorder, ...
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least ...
Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study Tissue frataxin (FXN) levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results